Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002345 · ClinicalTrials.gov registry record · Phase 4
The Safety and Effectiveness of Megace in HIV-Infected Women
A Phase 4 study of HIV Infections and Cachexia, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT00002345 is a Phase 4 study of HIV Infections and Cachexia that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00002345, a Phase 4 study of HIV Infections and Cachexia, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.
Conditions Studied
Interventions
- DRUG Megestrol acetate
Study Locations (4)
California
- Univ of California - Davis Med Ctr / CARES - Sacramento
Connecticut
- Yale Univ Med School - New Haven
District of Columbia
- Georgetown Univ Med Ctr - Washington D.C.
Rhode Island
- Miriam Hosp - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002345
The ClinicalTrials.gov registry entry for NCT00002345 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Megestrol acetate is the first listed.
NCT00002345 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Connecticut, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002345 about?
NCT00002345 is a clinical study titled "The Safety and Effectiveness of Megace in HIV-Infected Women". To further evaluate the safety of megestrol acetate (Megace) oral suspension in the treatment of anorexia and cachexia in HIV-positive women. To compare the effectiveness of 2 doses of Megace by measurement of weight gain, appetite grade, and other parameters at 12 and 24 weeks.
What is the current status of trial NCT00002345?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants.
What conditions does trial NCT00002345 study?
This clinical trial studies the following conditions: HIV Infections, Cachexia, Anorexia.
What interventions are being tested in trial NCT00002345?
The interventions under investigation include: Megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00002345?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002345 being conducted?
This trial has 4 study locations across California, Connecticut, District of Columbia, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.